• Je něco špatně v tomto záznamu ?

Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC)

E. Laukhtina, H. Mostafaei, D. D'Andrea, B. Pradere, F. Quhal, K. Mori, N. Miura, VM. Schuettfort, R. Sari Motlagh, A. Aydh, M. Abufaraj, PI. Karakiewicz, D. Enikeev, S. Kimura, SF. Shariat

. 2021 ; 39 (6) : 1961-1968. [pub] 20200817

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025705
E-zdroje Online Plný text

NLK ProQuest Central od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem

Odkazy

PubMed 32808107
DOI 10.1007/s00345-020-03384-9
Knihovny.cz E-zdroje

PURPOSE: The De Ritis ratio (aspartate aminotransferase/alanine aminotransferase, DRR) has been linked to oncological outcomes in several cancers. We aimed to assess the association of DRR with recurrence-free survival (RFS) and progression-free survival (PFS) in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: We conducted a retrospective analysis of 1117 patients diagnosed with NMIBC originating from an established multicenter database. To define the optimal pretreatment DRR cut-off value, we determined a value of 1.2 as having a maximum Youden index value. The overall population was therefore divided into two De Ritis ratio groups using this cut-off (lower, < 1.2 vs. higher, ≥ 1.2). Univariable and multivariable Cox regression analyses were used to investigate the association of DRR with RFS and PFS. The discrimination of the model was evaluated with the Harrel's concordance index (C-index). RESULTS: Overall, 405 (36%) patients had a DRR ≥ 1.2. On univariable Cox regression analysis, DRR was significantly associated with RFS (HR: 1.23, 95% CI 1.02-1.47, p = 0.03), but not with PFS (HR: 0.96, 95% CI 0.65-1.44, p = 0.9). On multivariable Cox regression analysis, which adjusted for the effect of established clinicopathologic features, DRR ≥ 1.2 remained significantly associated with worse RFS (HR:1.21, 95% CI 1.00-1.46, p = 0.04). The addition of DRR only minimally improved the discrimination of a base model that included established clinicopathologic features (C-index = 0.683 vs. C-index = 0.681). On DCA the inclusion of DRR did not improve the net-benefit of the prognostic model. CONCLUSION: Despite the statistically significant association of the DRR with RFS in patients with NMIBC, it does not seem to add any prognostic or clinical benefit beyond that of currently available clinical factors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025705
003      
CZ-PrNML
005      
20211026133600.0
007      
ta
008      
211013s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00345-020-03384-9 $2 doi
035    __
$a (PubMed)32808107
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
245    10
$a Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC) / $c E. Laukhtina, H. Mostafaei, D. D'Andrea, B. Pradere, F. Quhal, K. Mori, N. Miura, VM. Schuettfort, R. Sari Motlagh, A. Aydh, M. Abufaraj, PI. Karakiewicz, D. Enikeev, S. Kimura, SF. Shariat
520    9_
$a PURPOSE: The De Ritis ratio (aspartate aminotransferase/alanine aminotransferase, DRR) has been linked to oncological outcomes in several cancers. We aimed to assess the association of DRR with recurrence-free survival (RFS) and progression-free survival (PFS) in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: We conducted a retrospective analysis of 1117 patients diagnosed with NMIBC originating from an established multicenter database. To define the optimal pretreatment DRR cut-off value, we determined a value of 1.2 as having a maximum Youden index value. The overall population was therefore divided into two De Ritis ratio groups using this cut-off (lower, < 1.2 vs. higher, ≥ 1.2). Univariable and multivariable Cox regression analyses were used to investigate the association of DRR with RFS and PFS. The discrimination of the model was evaluated with the Harrel's concordance index (C-index). RESULTS: Overall, 405 (36%) patients had a DRR ≥ 1.2. On univariable Cox regression analysis, DRR was significantly associated with RFS (HR: 1.23, 95% CI 1.02-1.47, p = 0.03), but not with PFS (HR: 0.96, 95% CI 0.65-1.44, p = 0.9). On multivariable Cox regression analysis, which adjusted for the effect of established clinicopathologic features, DRR ≥ 1.2 remained significantly associated with worse RFS (HR:1.21, 95% CI 1.00-1.46, p = 0.04). The addition of DRR only minimally improved the discrimination of a base model that included established clinicopathologic features (C-index = 0.683 vs. C-index = 0.681). On DCA the inclusion of DRR did not improve the net-benefit of the prognostic model. CONCLUSION: Despite the statistically significant association of the DRR with RFS in patients with NMIBC, it does not seem to add any prognostic or clinical benefit beyond that of currently available clinical factors.
650    _2
$a senioři $7 D000368
650    _2
$a alanintransaminasa $x krev $7 D000410
650    _2
$a aspartátaminotransferasy $x krev $7 D001219
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $x epidemiologie $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory močového měchýře $x krev $x patologie $x chirurgie $7 D001749
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Hospital of Tours, Tours, France
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Miura, Noriyoshi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
700    1_
$a Aydh, Abdulmajeed $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u King Faisal Medical City, Abha, Saudi Arabia
700    1_
$a Abufaraj, Mohammad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan $u The National Center for Diabetes, Endocrinology and Genetics, The University of Jordan, Amman, Jordan
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Enikeev, Dmitry $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Kimura, Shoji $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u European Association of Urology Research Foundation, Arnhem, The Netherlands. shahrokh.shariat@meduniwien.ac.at
773    0_
$w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 6 (2021), s. 1961-1968
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32808107 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133606 $b ABA008
999    __
$a ok $b bmc $g 1714653 $s 1146212
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 6 $d 1961-1968 $e 20200817 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace